Molecular Subtype-Guided Postoperative Radiotherapy for Phyllodes Tumor of the Breast: A Randomized Controlled Trial

NCT07657169 · tracked via the Priya Life Science China tracker

Sponsor

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Phase

Not applicable

Started

2026-06-01

Last updated

2026-06-18

Condition(s) studied

Radiotherapy, AdjuvantPhyllodes Breast TumorPrognosisMolecular Typing

Investigational drug(s) / intervention(s)

Postoperative Radiotherapy (PORT)

Postoperative Radiotherapy (PORT): Radiotherapy delivered after R0 resection. For breast-conserving surgery: whole-breast irradiation (50 Gy in 25 fractions, 2 Gy/fraction, 5 fractions/week) followed by sequential tumor bed boost (10-16 Gy in 5-8 fractions, 2 Gy/fraction). For mastectomy: chest wall irradiation (50 Gy in 25 fractions). Techniques allowed: IMRT, VMAT, or TOMO. No routine regional nodal irradiation unless pathologically confirmed nodal involvement. Target volume and organ-at-risk constraints as per protocol (e.g., ipsilateral lung Dmean \<15 Gy, heart Dmean \<5 Gy for left-sided tumors). Acute and late toxicities assessed by CTCAE v5.0.

Study summary

Phyllodes tumor (PT) of the breast is a rare fibroepithelial neoplasm, and the role of postoperative radiotherapy (PORT) remains controversial. Our team has previously established a molecular subtyping system for PT, classifying patients into four subtypes. Among them, the malignant novel 1/2 (MN1/MN2) subtypes exhibit extremely high risk of local recurrence, and retrospective data suggest that PORT may significantly improve local control in these subtypes. This study aims to evaluate the efficacy and safety of molecular subtype-guided postoperative radiotherapy (PORT) in patients with MN-subtype phyllodes tumor of the breast. This prospective, multicenter, open-label, randomized controlled trial plans to enroll 160 patients with molecularly confirmed MN1 or MN2 subtype who have undergone R0 resection. Patients will be randomized in a 1:1 ratio to either the PORT group or the observation-only group, with stratification by negative margin width (\<1 cm vs. ≥1 cm) and molecular subtype (MN1 vs. MN2). The primary endpoint is 2-year local recurrence-free survival (LRFS). Secondary endpoints include distant metastasis-free survival (DMFS), disease-free survival (DFS), overall survival (OS), and the incidence of acute and late radiotherapy-related toxicities. By using an innovative molecular subtyping system to precisely select the target population, this study seeks to assess the benefit and safety of PORT in MN-subtype phyllodes tumors. The results are expected to provide the highest level of evidence for this specific subgroup, advance treatment strategies toward "molecular subtype-guided precision radiotherapy," improve patient outcomes, and inform future clinical guidelines.

Eligibility

Sex

FEMALE

Min age

18 Years

Max age

75 Years

Healthy volunteers

Inclusion Criteria: 1. Female patients aged ≥18 years and ≤75 years. 2. Histologically confirmed breast phyllodes tumor (PT) by the central laboratory, with molecular classification as MN1 or MN2 subtype via transcriptome sequencing or IHC; 3. Primary or ipsilateral local recurrence following R0 resection (negative margins) before enrollment; 4. Pathologically confirmed borderline or malignant PT; 5. No evidence of distant metastasis (M0); 6. ECOG performance status 0-1; 7. Signed informed consent before treatment; 8. Expected randomization and study entry within 8-12 weeks (no later than 16 weeks) after surgery. Exclusion Criteria: 1. Previous radiation to the same-side breast or chest; 2. women, or those of childbearing potential refusing effective contraception; Pregnancy, lactation, or refusal of contraception by fertile subjects; 3. Grade III-IV bone marrow suppression: WBC≤1.9\*109/L，ANC≤0.9\*109/L，PLT≤49\*109/L，AST, ALT≥2\*ULN; 4. Significant diarrhea, severe active infection, uncontrolled systemic disease, interstitial lung disease, active connective tissue disease, or LVEF \< 50%; 5. Significant diarrhea, severe active infection, uncontrolled systemic disease, interstitial lung disease, active connective tissue disease, or LVEF \< 50%; 6. Prior or planned systemic anti-tumor therapy (chemotherapy, targeted therapy, immunotherapy, or investigational agents) during the study; 7. Participation in other clinical trials that precludes study inclusion; 8. Any other condition that, in the opinion of the investigator, renders the patient unsuitable for the trial.

Primary outcome measure(s)

2-year Local Recurrence-Free Survival (LRFS) — From randomization up to 2 years post-randomization (primary analysis at 2 years)
Time from randomization to the first documented locoregional recurrence (ipsilateral breast/chest wall or regional lymph nodes) confirmed by imaging and/or pathology, or death from any cause, whichever occurs first. Patients alive without locoregional recurrence are censored at the date of last known follow-up.

Trial sites (4)

Facility	City	Region
Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University	Guangzhou	Guangdong
Peking University Shenzhen Hospital	Shenzhen	Guangdong
The Second Hospital of Shandong University	Jinan	Shandong
The Affiliated Hospital of Qingdao University	Qingdao	Shandong

More Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University trials in China

Induction Chemotherapy Plus Cadonilimab for Locally Advanced Cervical Cancer Active, not recruiting

OPtimizing REperfusion by Primary Intra-Arterial ThRomboLysis for Medium Vessel Occlusion Recruiting

Mycophenolate Mofetil in Gastrointestinal Henoch-Schonlein Purpura Recruiting

The Impact of Socioeconomic Determinants on the Patient Reported Outcomes in Young Breast Cancer Patients After Breast Surgery Recruiting

Comparing Endocrine Therapy Combined With High-Dose Palbociclib and Hydroxychloroquine to Endocrine Therapy Combined With Standard-Dose Palbociclib for Hormone Receptor-Positive and HER2-Negative Advanced Breast Cancer Starting soon

Other trials for the same condition

AI-Assisted System for Accurate Diagnosis and Prognosis of Breast Phyllodes Tumors Recruiting

Fertility Outcomes In Young Breast Cancer Patients And Their Prognosis And Offspring Health Enrolling by invitation

Stereotactic Radiosurgery Prognosis Assessment for Spinal Tumors Based on Radiomics Starting soon

Sentinel Lymph Node Sampling for Patients With Middle-high Risk Endometrial Cancer Confined to the Uterus Active, not recruiting

Validation of RCC Predicting Model With Emulated-target Trial Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07657169 on ClinicalTrials.gov ↗ ← All trials in China